UROXATRAL Drug Patent Profile
✉ Email this page to a colleague
When do Uroxatral patents expire, and when can generic versions of Uroxatral launch?
Uroxatral is a drug marketed by Concordia and is included in one NDA.
The generic ingredient in UROXATRAL is alfuzosin hydrochloride. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the alfuzosin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Uroxatral
A generic version of UROXATRAL was approved as alfuzosin hydrochloride by APOTEX INC on July 18th, 2011.
Summary for UROXATRAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Clinical Trials: | 4 |
| Patent Applications: | 267 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for UROXATRAL |
| What excipients (inactive ingredients) are in UROXATRAL? | UROXATRAL excipients list |
| DailyMed Link: | UROXATRAL at DailyMed |
Recent Clinical Trials for UROXATRAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospitals Cleveland Medical Center | N/A |
| Sanofi | N/A |
| University of Pennsylvania | Phase 3 |
Pharmacology for UROXATRAL
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for UROXATRAL
Paragraph IV (Patent) Challenges for UROXATRAL
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| UROXATRAL | Extended-release Tablets | alfuzosin hydrochloride | 10 mg | 021287 | 9 | 2007-06-12 |
US Patents and Regulatory Information for UROXATRAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordia | UROXATRAL | alfuzosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021287-001 | Jun 12, 2003 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for UROXATRAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Concordia | UROXATRAL | alfuzosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021287-001 | Jun 12, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| Concordia | UROXATRAL | alfuzosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021287-001 | Jun 12, 2003 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for UROXATRAL
See the table below for patents covering UROXATRAL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 1228700 | ⤷ Try a Trial | |
| Poland | 331862 | ⤷ Try a Trial | |
| Argentina | 009312 | COMPRIMIDO FARMACEUTICO DESTINADO A LA VIA ORAL, PARA LA LIBERACION CONTROLADA DE CLORHIDRATO DE ALFUZOSINA AL NIVEL DE LOS SEGMENTOS PROXIMALES DEL TRACTO GASTROINTESTINAL Y COMPOSICION FARMACEUTICA QUE COMPRENDE UNO O VARIOS COMPRIMIDOS. | ⤷ Try a Trial |
| France | 2582513 | COMPOSITIONS PHARMACEUTIQUES CONTENANT DE L'ALFUZOSINE | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 9808515 | ⤷ Try a Trial | |
| Czech Republic | 9900655 | ⤷ Try a Trial | |
| Slovakia | 27099 | TABLET WITH CONTROLLED RELEASE OF ALFUZOSINE CHLORHYDRATE | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
